Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Crizotinib
Related studies linked through entity extraction aliases.
Drug Drug Interaction Study Of Crizotinib With Esomeprazole.
- Status
- COMPLETED
- Phase
- PHASE1
Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations
- Status
- COMPLETED
- Phase
- PHASE1
A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study to Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function
- Status
- COMPLETED
- Phase
- PHASE1
Relative Bioavailability Of A Crizotinib Oral Liquid Formulation To Crizotinib Formulated Capsule
- Status
- COMPLETED
- Phase
- PHASE1
A Phase 1 Absolute Bioavailability Study For Oral Crizotinib In Healthy Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
Bioequivalence And Food Effect Study Comparing The Commercial Formulation Of Crizotinib To Its Clinical Study Formulations And Commercial Formulation With Or Without Food In Healthy Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
Estimation Of Effect Of Ketoconazole On Pharmacokinetics Of Crizotinib In Healthy Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
Estimation Of Effect Of Rifampin On Pharmacokinetics Of Crizotinib In Healthy Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
A Study To Investigate The Taste Of Crizotinib Liquid In Trained Healthy Adult Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)
- Status
- TERMINATED
- Phase
- PHASE1
Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials
- Status
- COMPLETED
- Phase
- NA